IceCure Medical gains after ProSense update, $5.5M placement
NEW YORK, June 18, 2026, 07:07
Legend Biotech jumps 42% as traders look at results from small cancer study
Legend Biotech Corporation shares are coming off a 42% rally on Tuesday, trading on the Nasdaq. Investors are still digesting early cancer-drug trial results that lifted hopes for the pipeline behind the company’s approved multiple myeloma drug Carvykti.
Bluejay Diagnostics Gains Pre-Market on U.S. Manufacturing Agreement
Bluejay Diagnostics rallied in premarket trade Tuesday after saying it will partner with Argonaut Manufacturing Services on U.S. production for its Symphony near-patient test system. Shares were up 148.4% at $5.39 at 8:43 a.m. EDT, according to StockAnalysis, after closing Monday much lower. Benzinga had BJDX quoted at $6.79, up 212.9%.
Cigna’s Obamacare Exit Puts 369,000 Members on the Clock for 2027 Coverage
Cigna Group plans to exit the Affordable Care Act individual insurance market after 2026, which means around 369,000 members in 11 states will need to find new coverage for 2027. That’s another blow for a marketplace already grappling with cost pressures. The ACA marketplaces—commonly known as Obamacare—offer policies for people who purchase insurance independently instead of getting it through work.
Roche share price set for Monday test after MS drug fenebrutinib data lands
Roche Holding is drawing attention as Swiss markets reopen Monday, following word from the drugmaker that its investigational multiple sclerosis therapy, fenebrutinib, met its primary endpoint in a late-stage trial targeting primary progressive multiple sclerosis. Roche closed out Friday at 356.40 Swiss francs, down 0.6%.
Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus
Pfizer shares climbed 72 cents, or 2.7%, to $27.22 in afternoon trading Friday, outpacing the SPDR S&P 500 ETF’s roughly 1.7% gain. Roughly 30 million Pfizer shares traded hands.
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week
Pfizer shares dropped 1.8% to $26.02 in early afternoon trading, having fluctuated between $25.97 and $26.39.
Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal
Eli Lilly and Company shares dipped roughly 2.4% to $1,015.05 on Wednesday, following a close of $1,039.51 the day before. Intraday, the stock fluctuated between $1,012.09 and $1,038.96.
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next
Shares of Johnson & Johnson ticked up Tuesday following U.S. regulatory clearance to broaden the indication for its Darzalex Faspro treatment in newly diagnosed multiple myeloma, a type of blood cancer. The stock ended the session 1.34% higher at $224.46 and showed little movement after hours.
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list
Eli Lilly and Company shares ended Tuesday down $24.22, or roughly 2.3%, at $1,039.51. In after-hours trading, the stock edged up about 0.3% to $1,042.50. The U.S. Centers for Medicare & Medicaid Services announced it selected Lilly’s Trulicity, a type 2 diabetes drug, along with 14 other medicines for 2028 price negotiations. This marks the first time the list includes some therapies covered under Medicare Part B. Last year, the agency projected that negotiated prices for the 15 drugs chosen for 2027 would cut annual spending by 36%, roughly $8.5 billion, compared to recent costs.
GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+
GSK announced that the European Commission has greenlit its RSV vaccine Arexvy for adults 18 and older, expanding eligibility beyond those 60-plus and high-risk individuals aged 50 to 59. “This approval helps protect all adults aged 18 and older in Europe against RSV,” said Sanjay Gurunathan, GSK’s head of Vaccines and Infectious Diseases R&D. The approval applies across EU member states and countries in the European Economic Area. GSK pointed to an average of 158,000 RSV-related adult hospitalisations annually within the EU.
GSK share price: China’s Trelegy asthma nod puts the stock in focus for Monday — what to watch next
Shares of GSK plc are set to draw attention when London trading resumes Monday, following news that China approved a new asthma indication for its Trelegy Ellipta inhaler. On Friday, the stock closed down 3.5 pence, or 0.19%, at 1,801 pence, with around 9 million shares changing hands.
GSK share price in focus after China clears Trelegy for asthma — what to watch next week
GSK plc shares slipped 0.2% to 1,801 pence on Friday following news that China approved Trelegy Ellipta for adults with uncontrolled asthma. With London trading closed for the weekend, investors will have to wait until Monday to assess the impact of the new label.
ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update
ImmunityBio shares jumped on Friday and look set to remain in the spotlight when U.S. markets open again. The company revealed a steep rise in preliminary sales for its bladder cancer immunotherapy ANKTIVA, alongside a quicker-than-anticipated pace in trial enrollments.
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows
Shares of Summit Therapeutics Inc dropped roughly 11% to $17.46 Monday afternoon, after fluctuating between $20.30 and $16.51. The move came following the company’s announcement that it filed a U.S. biologics license application for its lung cancer drug ivonescimab.
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic
Novo Nordisk’s U.S.-listed shares gained 1.4% to $57.34 in premarket trading on Friday after the company rejected claims involving SaveRxCanada.to, a Canadian online pharmacy platform that says it offers India-sourced Ozempic to U.S. patients. SaveRxCanada.to said the pens start at about $280 each, compared with typical U.S. retail prices of $900 to $1,100. A Novo spokesperson said: “We have no customer or partner relationship with this company/platform, and Ozempic from India has not been provided to them.”
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus
Merck & Co shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics and expected to finish the acquisition through a merger later in the day. The company said the deal will be treated as an asset acquisition, lifting 2026 research and development expense by about $9.0 billion and cutting earnings per share by roughly 30 cents in the first 12 months. “The acquisition of Cidara strengthens and complements our expanding respiratory portfolio,” Chief Executive Robert M. Davis said. Merck.com
Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026
Eli Lilly and Co shares slipped in after-hours trading on Wednesday. The stock was down about 0.5% at $1,074.68, after trading between $1,074.39 and $1,083.25 during the day on roughly 1.5 million shares.
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades
Vanda Pharmaceuticals’ shares surged about 18% in premarket trading on Wednesday after the U.S. Food and Drug Administration approved its motion-sickness vomiting drug, Nereus. StockAnalysis+1
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)
SELLAS Life Sciences Group, Inc. is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility.